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Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19
mortality. Furthermore, sex differences influence the frequency and severity of pharmaco-
logical side effects. A large number of clinical trials to develop new therapeutic approaches
and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender
in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to
January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 stu-
dies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan
sex-matched or representative samples or emphasized sex/gender reporting, and only 178
(4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight
(17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until
December 15, 2020 report sex-disaggregated results or subgroup analyses.
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Available data point towards an increased risk of mortalityfor male patients with COVID-19 worldwide compared tofemale patients1. This could be related to intrinsic sex
differences in the immune reaction2 or specific characteristics of
the SARS-CoV-2 infectious process. The virus connects to the
ACE2 receptor, which is encoded on the X chromosome and co-
engages a serine protease – TMPRSS2 – that appears to be
hormone-sensitive3. Reports also highlight the role of the innate
immune response in the fight against the virus; specifically of
TLR-74, which is also encoded on the X chromosome. TLR-7 has
been previously described as a relevant modulator of sex-specific
differences in anti-viral immunity5. The investigation of sex dif-
ferences could provide essential insights into COVID-19 patho-
physiology and possibly aid the identification of effective
interventions. In addition to the study of sex differences, gender-
sensitive analysis is warranted6. Gender, a multidimensional
variable describing identity, norms and relations between
individuals7, can influence access to testing, diagnosis, medical
care, and pharmacological treatments, and significantly affect the
availability of social, economic, and logistic support6. Gender can
also influence preventative and risk behavior, possibly impacting
the course of the infection8. Both sex and gender can influence
the pharmacokinetics, pharmacodynamics, and the safety profile
of drugs9,10.
Several calls urging the inclusion of sex and gender into
COVID-19 trials have been published6,11,12. Excluding one sex
from clinical trials and not disaggregating results by sex can lead
to an increased incidence of unwanted side effects in the untested
population13 due to overmedication and other factors14. Not
addressing the gender dimension hampers the opportunity to
reduce inequality in healthcare, promote preventative action and
modulate the course of the infection and pharmacological
access15. Given these potential health risks for a large fraction of
the infected population, we investigated the consideration of sex
and/or gender as an analytical variable in currently registered and
published trials for SARS-CoV-2/COVID-19.
In this work we show that attention to sex and gender at the
registration and publication stages for COVID-19 studies is
generally low. Only 178 (4%) of the 4420 studies in our Clin-
icalTrials.gov sample mention a plan to include sex/gender as an
analytical variable, a further 237 (5.4%) plan sex-matched or
representative samples or emphasized sex/gender reporting and
935 (21.2%) only mention sex/gender in the context of a
recruiting statement. The majority of the sample (2946 studies,
66.7%) makes no mention of sex/gender in the study registration.
Of the 45 publications for randomized control trials (RCTs) of
pharmacological interventions for COVID-19 we identified, eight
(17.8%) report sex-disaggregated results or subgroup analyses.
Results
Sex and gender in clinical study registrations. We identify 4420
registered SARS-CoV-2/COVID-19 studies, of which 1659 are
observational and 2475 interventional. Of the interventional
trials, 1161 are randomized controlled trials (RCTs) of pharma-
cological (drug and biological/vaccine) interventions. In addition,
we identify 260 patient registry studies and 26 expanded access/
compassionate use studies (Fig. 1, for further specifications see
Methods section).
Of the 4420 registered studies, 935 studies (21.2%) explicitly
address sex/gender solely as a recruitment criterion, and only
178 studies (4%) mention sex/gender as a planned analytical
variable. A further 237 (5.4%) plan sex-matched or representative
samples (65) or emphasize sex/gender reporting (172). 124 studies
(2.8%) focus solely on one sex, with 100 recruiting only female
participants and 24 only male ones. Female-only studies mostly
focus on the relation between COVID-19 and pregnancy
outcomes. One study explicitly addresses the impact of
COVID-19 on the transgender population. As for the remainder
of the studies, 2906 (65.7%) do not address sex/gender in the
study protocol registration on ClinicalTrials.gov beyond the
mandated selection from a list of the eligible groups for the study
(‘Male’, ‘Female’, or ‘All’), and 40 have a spurious mention
unrelated to recruitment or analytical decisions. Of the
4420 studies, only 346 (7.8%) explicitly mention “gender” (in
any context) in the sections of the study protocol targeted by our
search (see Methods section). The level of detail in the study
records is very variable. Only 70.1% (3100) include any
information in the detailed description field and only 132 attach
supporting pdfs (79 included statistical analysis plans). The
median total word count across the two study description fields
(brief and detailed) is 245 for the observational studies, 260 for
the other interventions, and 214 for pharmacological RCTs.
As displayed in Fig. 2, attention to sex/gender in the study
design and registration phase is generally low and varies by study
type. The study protocols that mention sex/gender as an
analytical variable are mostly observational and patient registry
studies (132, 74.2%), as are those with sex/gender matching/
reporting (153, 64.6%). Interventional protocols are dominated by
studies that only discuss sex/gender in the context of recruitment
and studies with no mention of sex/gender at all. Only 15 (1.3%)
of the 1161 pharmacological intervention RCTs and 31 (2.4%) of
the 1314 other interventional studies have registered a plan to
consider sex as a variable upon analysis.
Studies intending to conduct sex-analyses are larger on average
(median: 700 anticipated participants) than those with no sex
mention at all (median: 176 anticipated participants), but again
study type plays a role. Observational and patient registry studies
enroll 287 and 400 patients on average, compared to 160 and 100
for pharmacological RCTs and other intervention trials. Phase
information is provided for 1583 (64%) of the other intervention
and pharmacological RCTs, and are dominated by phase 2 and
3 studies (70.1%, 1109 studies). The US is the most common host
country of participating facilities; 1003 of the studies have at least
one recruiting location in the US, followed by France (603), the
United Kingdom (228), Italy (213), and Spain (211) (see
Supplementary Fig. 2). Of studies with a recruiting facility based
in the United States (US), 242 (24.2%) are observational and 2.1%
(21) plan sex/gender analysis. Of those with no US presence, 1417
(41.4%) are observational and 4.6% (157) plan sex/gender analysis
(see Fig. 2).
Registration patterns during the pandemic. Our analysis shows
that attention to sex/gender in trial registrations remained low
throughout the pandemic. Monthly study registrations (as mea-
sured by date first submitted to ClinicalTrials.gov) peaked in late
spring and early summer of 2020 (see Supplementary Fig. 1, panel
B) and 56% (2475) of our sample was submitted in the first half of
2020. Of the 2475 studies submitted in the first half of 2020, 102
(4.1%) indicate a plan to include sex as an analytical variable,
while 76 (3.9%) of the 1945 submitted in the second half indicate
such a plan. The level of other mentions (sex-matching, sex-
representative sample, explicit statement of intent to record, and
report sex/gender etc.) also remained low throughout the year.
Supplementary Figure 1, panel A, plots developments in the level
of attention to sex and gender per month, from January 2020 to
January 2021.
As of 26 January 2021, 639 registered studies are completed,
and 18 of them have reported results on ClinicalTrials.gov. Of
these, one registration is a female-only study. Of the remaining
17, three have indicated an intent to include sex/gender as an
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analytical variable upon registration, while none have uploaded
sex-based analysis as part of their results.
Sex and gender in trial publications. A PubMed search of
published RCTs retrieved 957 results of which 56 (6%) are ori-
ginal reports of RCTs (for further specifications see Data and
Methods section). Eleven are excluded due to a focus on non-
pharmacological COVID-19-related interventions. Fourteen trials
are phase III, the others phase I and II. All of the remaining 45
trials report the number of female and male participants. Of
these, 4 (9%) adjust their analysis by sex/gender and 8 (17.8%)
report sex-disaggregated analyses. These analyses are e.g. pre-
specified subgroup analyses, sex-specific reporting of side effects
or sex-stratified analyses.
Discussion
Although sex appears to be an important determinant of mor-
tality risk and immunologic responses to COVID-195,16,17, cur-
rently registered clinical trials mostly omit sex as an explicit
recruitment or analytical criterion. Of the identified RCT pub-
lications, only 17.8% report sex-specific analyses or disaggregate
their results by sex. This suggests that only a small share of the
studies lacking consideration of sex upon registration at Clin-
icalTrials.gov, account for sex during trial execution and report-
ing, leading to a significant information gap. Gender is given even
less consideration. Very few studies address gender as a recruit-
ment or analytical variable. This applies equally to observational
and interventional trials.
As research into COVID-19 pathophysiology and pharmacolo-
gical interventions has led to substantial knowledge gain, the impact
of sex and gender differences on these factors has also become more
evident. Research demonstrates the impact of sex on clinical
presentation18, severity of disease19, and treatment allocation20. The
incidence of side effects with hydroxychloroquine21 or anaphylaxis
upon vaccination22 are both higher in female subjects. Furthermore,
the recently reported sinus vein thromboses associated with two of
the vector-based vaccines also appear to affect female subjects more
often23,24. These reports confirm the previously described dis-
crepancies in sex-specific pharmacological response14 and highlight
the need for sex-disaggregated data collection, analysis, and
reporting. However, despite increasing awareness, the level of
attention to sex and gender in ClinicalTrials.gov registrations
remained low and relatively stable from January 2020 to
January 2021.
Several aspects need to be taken into consideration when
looking at our findings. First, the size of trials might impact the
inclusion of sex as an analytical variable. Interventional trials in
the sample tended to be smaller, which might limit the ability of
experimenters to disaggregate analyses while maintaining statis-
tical power. The small sample sizes may partly be explained by
experimenters facing challenges with participant enrollment25.
However, given the striking sex and gender differences identified
for this disease, a lack of consideration of these variables could
undermine the reproducibility and generalizability of the results.
Ignoring sex and gender aspects of COVID-19 is not scientifically
or ethically justifiable, and interventional trials should be
designed to account for these variables. Second, disciplinary
culture might affect the decision to perform sex and gender-
sensitive analysis. For example, researchers conducting large
observational studies might be trained to consider a vast array of
social determinants, which biomedical researchers might not
prioritize in interventional trials. Our results reflect these differ-
ences, as observational studies appeared to mention sex and
Fig. 1 Study types and allocation into sex/gender (S/G) attention groups for the COVID-19 sample. The left-hand (green) panel shows the distribution
of the 4420 identified studies across study types. We created the (Pharmacological) RCT label following the procedure outlined in Methods section, the
other classifications are taken from ClinicalTrials.gov. The right-hand panel (blue) shows the distribution of studies across the various mutually exclusive
sex/gender groups we defined (see Methods section). In the ‘Some S/G mention’ set there is a hierarchy. The most extensive consideration was sex/
gender as an analytical variable and after that sex/gender matching/representation, followed by explicit statements of intent to record or report participant
sex/gender. Finally, the ‘Recruitment Only’ contains those studies whose only sex/gender mention was in a recruiting context. We allocated the studies to
one of the categories based on the highest category of S/G consideration. For instance, if they reported attention to S/G in analysis and recruiting, we only
counted them in analysis.
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gender more frequently in their registration files. In addition to
sex and gender, this type of research highlights the impact of a
wide range of social determinants on the development of
COVID-19, including poverty26, racialized disparities27, and the
impact of social context28. Biomedical research into the viral
dynamics in people cannot ignore these determinants. Third,
national requirements for trial performance might play a role in
the decision to include sex and/or gender as analytical variables.
We chose to examine the ClinicalTrials.gov database because of
the quality and detail of its registrations and because the US has
clear guidance on the need for consideration of sex (and gender)
in clinical studies29. However, by focusing on ClinicalTrials.gov,
we will have missed a large proportion of studies conducted
outside of the US, which limits the global validity of our findings.
Finally, researchers may not be providing sufficient detail on
their planned analyses upon study registrations for us to detect the
true level of attention they afford sex and gender. However, given
that only 17.8% of the published trials reported sex-disaggregated
analyses, a lack of detail upon registration does not appear to be
substantially corrected during the execution, analysis, and publica-
tion process for the vast majority of trials. An enforced requirement
of analytical details and quality control upon registration could
possibly increase the consideration of sex and gender in clinical
trials and improve the reliability of the published results.
In light of the current results, we urge researchers working in
the field of SARS-CoV2 and COVID-19 to systematically apply
a sex-specific methodology. This entails: (a) the recording of
sex of all participants; (b) the inclusion of sex as an indepen-
dent variable into multivariate analysis; (c) the performance of
sex-disaggregated analyses; and (d) the reporting of sex-
disaggregated results for unambiguous identification of dif-
ferences in effectiveness, side effects, and mortality30. In
addition, data for trials that record the sex/gender of partici-
pants, but are not statistically powered to disaggregate results
by sex, should be made publicly available for pooling in evi-
dence synthesis. More comprehensive analyses should address
gender-related impacts31 and utilize intersectional approaches
to identify specific subgroup experiences and barriers to
access32.
The current experiences should inform future preparedness
efforts. A general sex- and gender-sensitive approach should be
structurally implemented through mandatory reporting require-
ments upon registration of clinical trials. This policy should be
institutionalized to guarantee its application also in times of crisis.
The striking sex differences in COVID-19 mortality highlight a
need for universal consideration of these variables. Sex-specific
analysis cannot be an afterthought once the acute phase has
passed; it is proving to be an important contributor to the dis-
section of disease-specific mechanisms17. Investigating sex dif-
ferences can highlight otherwise ignored mechanisms and should,
hence, be an essential component of robust, reproducible, and
socially relevant research.
Fig. 2 Properties of COVID-19 Studies in the sample and level of attention to sex/gender (S/G). Sex/gender coding and properties of studies at time of
data collection on 26 January 2021. Studies are reported according to different analytical criteria. Color blocks represent one category of analysis. Studies
are exclusively allocated to one category per analysis, with the exception of the “intervention” category. Here, studies can propose multiple interventions
and, hence, appear under each unique intervention type they include. In the facility section, we focus on the number (single or multiple) and location (US or
non-US) of the facilities recruiting participants into the studies. Address information for facilities is available for 89% of our full COVID-19 set. All studies
(except the 26 Expanded Access) provide enrollment details and they are mostly ‘anticipated’, i.e. target numbers (80%).
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Methods
Data was obtained through a query of the relational database “Aggregate Analysis
of ClincalTrials.gov” (AACT)33 on 26 January 2021. AACT contains all publicly
available ClinicalTrials.gov data.
Selection of the COVID-19 studies. In our search for COVID-related studies, we
targeted the following trial-registration fields: the official and brief trial titles, the brief
summary, the detailed description and conditions, as well as the titles and descriptions
of outcome measures (primary, secondary, and other). The search terms used were:
Coronavirus, Corona Virus, SARS-CoV-2, SARS CoV2, SARSCoV2, COVID, 2019
nCov, and 2019nCoV. The search was case-insensitive and blind to use of hyphens.
Ninety eight percent of the protocols in our final sample had one of these search
terms in their titles or conditions. The remaining 2% included studies, where COVID-
19 or its synonyms were mentioned in the primary outcome measures or appeared in
at least two other relevant fields, e.g. in a description of a non-primary outcome
measure AND in the brief summary or detailed description. We adopted this
approach to avoid including study registrations that mention COVID-19 but do not
focus on health aspects directly related to the virus. Our approach was based on what
we learned in an earlier round of analysis, where we manually inspected all studies
without a COVID-19 term in the titles or conditions.
Our analysis covered registrations with a starting or submission date (if no
starting date was available) between 1 January 2020 and 26 January 2021. We
removed duplicate registrations and studies listed as ‘Withdrawn’ or ‘No longer
available’, leaving us with a final sample of 4420 studies.
Identification of attention to sex and gender. ClinicalTrials.gov mandates
researchers to state the sexes eligible for their study by selecting one option from a
pre-defined list (‘All’, ‘Male’ or ‘Female’). We used this data element to identify
single-sex study designs. For registrations open to ‘All’ sexes, we identified atten-
tion to sex/gender by searching for the following terms (and their plurals): sex,
gender, woman, female, man, male, girl, boy, pregnan*, and transg*.
We restricted these searches to the following registration fields: titles, brief
summary, detailed description, eligibilities (population, gender, and inclusion
criteria), study design group descriptions and titles, intervention descriptions, and
primary, secondary, and other outcomes.
Two independent coders (EB and SOP) went through all registrations
mentioning sex or gender-related terms, assigning each registration to one of the
following categories: (a) sex/gender as an analysis criterion; (b) other sex/gender
mentions (c) sex/gender recruitment; and (d) no relevant sex/gender mention. As
of 26 January 2021, 79 studies had uploaded supporting pdf documents with
indications that they included a statistical analysis plan and 76 of these were open
to all sexes. We performed the same sex term search and coding on these 76
documents.
For inclusion into category (a) (analysis criterion), we looked for evidence of
intention to include sex/gender as an analytical variable. For instance, if a
registration stated that results would be stratified by sex, sex-subgroup analyses
would be performed, sex would be included as a covariate, or that researchers
hypothesized that sex/gender would affect outcomes, we considered the study
permissible, and no further statistical details were expected. If sex/gender
representation and differences were addressed in an introduction or literature
summary but no mention was made in the outline of the data analysis protocol, we
did not consider the protocol eligible for inclusion in category (a). Similarly, if
‘demographic variables’ were included in the outline of the planned statistical
analysis, but sex/gender was not explicitly mentioned in that particular discussion,
we did not include that study. We did not consider the intention to sex-match the
treatment and control groups a strong enough signal of planned sex/gender
analysis, and coded registrations including such intentions separately in
category b).
We assigned protocols to category (b) (other sex/gender mentions) if they
explicitly stated that they would record or report the sex of the participants or
would sex match to controls, aim for a representative sample etc. None of these
protocols clearly indicated any intention to include the variable upon analysis.
Category (c) (sex/gender recruitment) consists of protocols that only addressed
sex/gender in the context of an explicit recruitment statement covering both sexes/
genders. The sole selection of “All” in the pre-defined sexes eligible for study field
was not considered sufficient, as this registration step does not represent a marker
of a specific focus on the topic. Likewise, a focus on the sex of donors or parents,
but not the recipients or children, who were the focus of the study, was not
considered sufficient for inclusion. Category (c) includes a dominant subset of
studies that were included automatically, i.e., without manual coding (777 of 935)
owing to their large number and the type of sex-term match. These were
studies that only mentioned sex/gender terms in the list of eligibility inclusion
criteria and nowhere else in the registration, implying they could only be
candidates for sex/gender recruitment. We caution that this subset may include
some noise (e.g. studies that specify the type of contraception that both sexes would
be required to use to be eligible for inclusion, while not having a separate explicit
recruitment statement). However, this possible bias would lead to an
overestimation rather than an underestimation for category (c).
Studies in category (d) (no sex/gender mention) either had no match to one of
our sex/gender search terms (the vast majority), or were spurious sex matches. The
latter set includes studies where, for example, the only mention of sex was in a
literature summary or in the context of contraception requirements and
pregnancy tests.
Identification of the pharmacological RCTs. Our COVID-19 sample contains
many studies that investigate the social impact of COVID-19 or the effect of the
pandemic on access to healthcare and treatment. These are mainly concentrated
amongst the observational studies. We created a separate ‘pharmacological RCT’
category, consisting of the drug and vaccine/biological interventional RCTs, to have
a sample of the most relevant and high-quality trials. We retained the rest of the
interventional trials (now labeled ‘Other Intervention’) in addition to the obser-
vational and patient registry registrations as they do contain research of disease
prevalence, progression, and wider effects on the population. ClinicalTrials.gov
does not have a pre-defined pharmacological RCT label. To create one, we made
use of several data elements, where ClinicalTrials.gov requires those registering
interventional studies to select an option from a pre-defined list. These data ele-
ments were study type, allocation into study groups, intervention type(s), and study
group type. We selected interventional studies with randomized allocation into
study groups, having least one drug or vaccine/biological intervention and a par-
ticipant group of type ‘placebo/sham comparator’ or ‘no intervention’. Since the
‘experimental’ and ‘active comparator’ group-type labels were attached to some
groups that were obvious controls, we also proceeded to search the group titles and
descriptions for occurrences of control and placebo. We collected a few more
studies by looking at the study titles and the descriptions of the interventions for
occurrences of RCT or random*+ control*/placebo*. Our final pharmacological
intervention RCT set has 1161 studies. All remaining interventional trials are
labeled ‘Other Intervention’.
Selection and coding of the COVID-19 publications. We searched the PubMed
database on 15 December 2020 for publications on SARS-CoV-2/COVID-19 trials
using the search strategy for COVID-19 provided by the Canadian Agency for
Drugs and Technologies in Health (CADTH)34 and the RCT search filter of the
Scottish Intercollegiate Guideline Network (SIGN)35, resulting in 957 unique article
records. Two independent coders (MWN and SOP) screened these 957 articles to
identify original publications of randomized controlled trials. We excluded com-
ments, reviews, observational studies, trial protocols, post-hoc analyses, non-
randomized trials, and RCTs not focusing on COVID-19.
Two independent coders (MWN and SOP) evaluated the degree of sex/gender-
specific analysis in the 56 original reports of RCTs. Sex/gender-specific analysis
could range from (a) sole mention of participating numbers of women/men in the
trial, (b) explicit incorporation of sex/gender as analytical variable, and (c)
reporting of sex/gender-disaggregated analyses.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data for this study was gathered from the following public repositories;
ClinicalTrials.gov study registration data from the Aggregate Analysis of ClincalTrials.
gov database (https://aact.ctti-clinicaltrials.org/) and publications from the PubMed
database of biomedical literature (https://pubmed.ncbi.nlm.nih.gov/). Data on our final
study and paper samples, which supports our main results, is available in an Excel file in
a public Github repository at https://github.com/bradyemer/Sex-gender-in-COVID-19-
trials (https://doi.org/10.5281/zenodo.4772598)
Code availability
The AACT database of ClinicalTrials.gov data was queried using R (v. 3.6.1). Python
(v. 3.8.5) was used to clean the data, create the COVID-19 and sex/gender candidate
samples, the final numbers for this paper and the supplementary figures. This work
was documented in a Jupyter (v. 4.6.3) Python 3 notebook. Manual classification of
study registrations with sex/gender terms and of the PubMed sample was documented
in Excel (v. 16.33). Figures 1 and 2 were created in R (v. 4.0.2). An R and Python-based
pipeline which reproduces our selection of the ClinicalTrials.gov COVID-19 sample
and sex/gender candidates is publicly available in a Github repository at https://github.
com/bradyemer/Sex-gender-in-COVID-19-trials (https://doi.org/10.5281/
zenodo.4772598)
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